硝苯地平联合瑞舒伐他汀对老年高血压病患者血压、血脂及颈动脉内膜中层厚度的影响被引量：3

在线阅读下载PDF

导出

摘要观察单用硝苯地平控释片、硝苯地平控释片与瑞舒伐他汀联用及依那普利片与瑞舒伐他汀联用对老年原发性高血压患者血压、血脂及颈动脉内膜中层厚度(IMT)的影响。方法:选择186例临床心血管危险分层在中危以上的1、2级老年高血压患者,随机分为钙离子通道阻滞剂(CCB)组(60例),血管紧张素转化酶抑制剂(ACEI)+瑞舒伐他汀组(62例)及钙离子通道阻滞剂(CCB)+瑞舒伐他汀组(64例),分别于用药前和用药12、24、48周后检测量血压,总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C),以IMT的变化。结果:①治疗后3组收缩压和舒张压均显著降低(P<0.05),他汀+CCB组的收缩压和舒张压下降更为显著(P<0.01)。②治疗后ACEI+他汀组及CCB+他汀组的TC和LDL-C均显著下降,治疗48周后CCB+他汀组下降明显(P<0.05)。③治疗后3组IMT均明显下降,并且治疗48周后CCB+他汀组与另两组比较,差异均有统计学意义(P<0.05)。结论:硝苯地平控释片与瑞舒伐他汀联合在降压、降脂、降低IMT方面具有一定的临床价值。

作者严军虎张淑娟

机构地区陕西师范大学医院陕西能源职业技术学院临潼医学校区

出处《陕西医学杂志》 CAS 2014年第6期749-751,共3页 Shaanxi Medical Journal

关键词高血压/药物疗法血脂障碍/药物疗法硝苯地平/治疗应用斯伐他汀/治疗应用老年人

分类号 R544.1 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献6

1中国高血压防治指南修订委员会.2013年中国高血压防治指南修订版[M].北京:人民卫生出版社,2013:20.
2马丽娜,冯明.老年原发性高血压动态血压及脉压的特点[J].心血管康复医学杂志,2009,18(5):465-467. 被引量：8
3Simons PC,Algra A,Bots ML,et al.Effect of nifedipine and cerivastatin on coronary endothelial function in patients with coronary artery disease:the EN-CORE I Study(Evaluation of Nifedipine and Cerivastatin On Recovery of coronary Endothelial function)[J].Cerivastatin,2003,107(3):422-428.
4Javad DM.Whaley Attenuation of NADPH oxidase activation and glomerular filtration barrier remodeling with statin treat-ment[J].Hypertension,2008,51:474.
5Miettinen TA,Gylling H.Synthesis and absorption markers of cholesterol in serum and lipoproteins during a large dose of statin treatment[J].Eur ClinInvest,2003,33(11):976-982.
6曾凯,陈良龙.他汀类药物非降脂作用研究新进展[J].心血管康复医学杂志,2006,15(2):201-203. 被引量：29

二级参考文献30

1张明华,刘国树,覃秀川,刘蓉.原发性高血压并发心脑血管疾病患者的危险因素分析[J].心血管康复医学杂志,2007,16(3):240-243. 被引量：5
2Lovett JK, Howard SC, Rothwell PM. Pulse pressure is independently associated with carotid plaque ulceration [J]. J Hypertens, 2003, 21 (9): 1669-1676.
3Asmar R, Safar M, Queneau P, et al. Pulse pressures an important tool in cardiovascular pharmacology and therapeutics [J]. Drugs, 2003, 63 (10): 927-932.
4Gordon SS. Systolic hypertension in the elderly: Pushing the frontiers of therapy-A suggested new approach [J]. J Clin Hypertens, 2004, 6 (4): 192--197.
5Marti'nez-Gonza'lez J, Raposo B, Rodriguez C, et al. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition prevents endothelial NO synthase downregulation by atherogenie levels of native LDLs: balance between transcriptional and posttranscriptional regulation [J]. Arterioscler Thromb Vasc Biol, 2001,21: 804.
6Feron O, Dessy C, Desager JP, et al. Hydroxy-methylglutarylcoenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance [J]. Circulation, 2001, 103:113-118.
7Laufs U, Liao JK. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase [J]. J Biol Chem, 1998, 273:24266-24271.
8Yamada M, Huang Z, Dalkara T, et al. Endothelial nitric oxide synthase-dependent cerebral blood flow augmentation by larginine after chronic statin treatment [J]. J Cereb Blood Flow Metab, 2000, 20; 709-717.
9Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, et al. Effects of the 3-hydroxy-3-methylglutaryl - CoA reduetase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells [J]. J Clin Invest, 1998, 101 (12):2711-2719.
10Rasmussen LM, Hansen PR, Nabipour MT, et al. Diverse effects of inhibition of 3 - hydroxy-3-methylglutaryl-CoA reductase on the expression of VCAM- 1 and E-selectin in endothelial cells [J]. Biochem J, 2001, 360: 363-370.